View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Aug. 31, 2014	Sep. 26, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	LANDEC CORP \CA\
Document Type	10-Q
Current Fiscal Year End Date	--05-31
Entity Common Stock, Shares Outstanding		26,866,078
Amendment Flag	false
Entity Central Index Key	0001005286
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Aug. 31, 2014
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands

Aug. 31, 2014

May 25, 2014

^[1]

Current Assets:

Cash and cash equivalents

$ 8,529

$ 14,243

Accounts receivable, less allowance for doubtful accounts of $491 and $516 at August 31, 2014 and May 25, 2014, respectively

43,458

44,421

Accounts receivable, related party

338

304

Income taxes receivable

1,020

2,000

Inventories, net

27,834

24,735

Deferred taxes

2,078

2,056

Prepaid expenses and other current assets

5,993

3,170

Total Current Assets

89,250

90,929

Investment in non-public company, non-fair value

793

Investment in non-public company, fair value

50,800

39,600

Property and equipment, net

76,946

74,140

Goodwill, net

49,620

Trademarks/tradenames, net

48,428

Customer relationships, net

8,499

8,720

Other assets

1,602

1,393

Total Assets

325,938

313,623

Current Liabilities:

Accounts payable

37,212

31,981

Accounts payable, related party

167

134

Accrued compensation

3,547

4,096

Other accrued liabilities

4,405

4,871

Deferred revenue

1,059

1,254

Current portion of long-term debt

6,980

6,055

Total Current Liabilities

53,370

48,391

Long-term debt, less current portion

33,051

28,317

Deferred taxes

30,584

30,133

Other non-current liabilities

1,403

2,021

Total Liabilities

118,408

108,862

Stockholders’ Equity:

Common stock, $0.001 par value; 50,000,000 shares authorized; 26,845,218 and 26,815,253 shares issued and outstanding at August 31, 2014 and May 25, 2014, respectively

Additional paid-in capital

131,833

131,488

Retained earnings

73,907

71,554

Total Stockholders’ Equity

205,767

203,069

Non-controlling interest

1,763

1,692

Total Equity

207,530

204,761

Total Liabilities and Stockholders’ Equity

$ 325,938

$ 313,623

[1]	Derived from audited financial statements.

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)
$ in Thousands

Aug. 31, 2014

May 25, 2014

^[1]

Allowance for doubtful accounts (in Dollars)

$ 491

$ 516

Common stock, par value (in Dollars per share)

$ 0.001

Common stock, shares authorized

50,000,000

Common stock, shares issued

26,845,218

26,815,253

Common stock, shares outstanding

26,845,218

26,815,253

[1]	Derived from audited financial statements.

Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Aug. 31, 2014	Aug. 25, 2013
Product sales	$ 133,614	$ 109,479
Cost of product sales	119,426	96,947
Gross profit	14,188	12,532
Operating costs and expenses:
Research and development	1,795	1,926
Selling, general and administrative	8,859	8,630
Total operating costs and expenses	10,654	10,556
Operating income	3,534	1,976
Dividend income	281	281
Interest income	93	60
Interest expense	(383)	(431)
Other income	200	5,400
Net income before taxes	3,725	7,286
Income tax expense	(1,301)	(2,475)
Consolidated net income	2,424	4,811
Non-controlling interest	(71)	(59)
Net income and comprehensive income applicable to common stockholders	$ 2,353	$ 4,752
Basic net income per share (in Dollars per share)	$ 0.09	$ 0.18
Diluted net income per share (in Dollars per share)	$ 0.09	$ 0.18
Shares used in per share computation
Basic (in Shares)	26,840	26,452
Diluted (in Shares)	27,267	27,081

Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands

3 Months Ended

Aug. 31, 2014

Aug. 25, 2013

Marketable Maturities [Member]

Cash flows from investing activities:

Proceeds from maturities of marketable securities

$ 1,665

Consolidated net income

$ 2,424

4,811

Depreciation and amortization

1,513

1,842

Stock-based compensation expense

398

278

Net loss on disposal of property and equipment

Deferred taxes

429

2,303

Change in investment in non-public company, fair value

(200)

(5,400)

Accounts receivable, net

963

3,099

Accounts receivable, related party

(34)

466

Income taxes receivable

936

161

Inventories, net

(3,099)

(476)

Issuance of notes and advances receivable

(1,656)

Collection of notes and advances receivable

255

Prepaid expenses and other current assets

(1,422)

Accounts payable

5,231

(2,387)

Accounts payable, related party

(489)

Accrued compensation

(549)

(129)

Other accrued liabilities

(1,084)

993

Deferred revenue

(195)

(620)

Net cash provided by operating activities

3,943

4,538

Purchases of property and equipment

(4,098)

(4,345)

Investment in non-public company, fair value

(11,000)

Purchase of marketable securities

(1,417)

Net cash used in investing activities

(15,098)

(4,097)

Cash flows from financing activities:

Proceeds from sale of common stock

250

Taxes paid by Company for stock swaps and RSUs

(12)

(1,210)

Proceeds from long-term debt

7,070

Payments on long-term debt

(1,411)

(1,383)

Proceeds from lines of credit

11,117

Payments on lines of credit

(11,117)

(2,950)

Change in other assets

(209)

Net cash provided by (used in) financing activities

5,441

(5,262)

Net decrease in cash and cash equivalents

(5,714)

(4,821)

Cash and cash equivalents at beginning of period

14,243

^[1]

13,718

Cash and cash equivalents at end of period

$ 8,529

$ 8,897

[1]	Derived from audited financial statements.

Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies

3 Months Ended

Aug. 31, 2014

Accounting Policies [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

1.	Organization, Basis of Presentation and Summary of Significant Accounting Policies

Organization

Landec Corporation and its subsidiaries (“Landec” or the “Company”) design, develop, manufacture and sell differentiated products for food and biomaterials markets and license technology applications to partners. The Company has two proprietary polymer technology platforms: 1) Intelimer® polymers, and 2) hyaluronan (“HA”) biopolymers. The Company sells specialty packaged branded Eat Smart® and GreenLine® and private label fresh-cut vegetables and whole produce to retailers, club stores and foodservice operators, primarily in the United States, Canada and Asia through its Apio, Inc. (“Apio”) subsidiary and sells HA-based biomaterials through its Lifecore Biomedical, Inc. (“Lifecore”) subsidiary. The Company’s HA biopolymers are proprietary in that they are specially formulated for specific customers to meet strict regulatory requirements. The Company’s polymer technologies, along with its customer relationships and trade names, are the foundation, and a key differentiating advantage upon which Landec has built its business.

Basis of Presentation

The accompanying unaudited consolidated financial statements of Landec have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions for Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring accruals) have been made which are necessary to present fairly the financial position at August 31, 2014, and the results of operations and cash flows for all periods presented. Although Landec believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information normally included in financial statements and related footnotes prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission. The accompanying financial data should be reviewed in conjunction with the audited financial statements and accompanying notes included in Landec's Annual Report on Form 10-K for the fiscal year ended May 25, 2014.

The results of operations for the three months ended August 31, 2014 are not necessarily indicative of the results that may be expected for an entire fiscal year because there is some seasonality in Apio’s food business, particularly, Apio’s Food Export business and the order patterns of Lifecore’s customers which may lead to significant fluctuations in Landec’s quarterly results of operations. In addition, the first quarter of fiscal year 2015 was a 14-week quarter which occurs once every six years compared to the standard 13-week quarter.

Basis of Consolidation

The consolidated financial statements are presented on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States and include the accounts of Landec Corporation and its subsidiaries, Apio and Lifecore. All material inter-company transactions and balances have been eliminated.

Arrangements that are not controlled through voting or similar rights are reviewed under the guidance for variable interest entities (“VIEs”). A company is required to consolidate the assets, liabilities and operations of a VIE if it is determined to be the primary beneficiary of the VIE.

An entity is a VIE and subject to consolidation, if by design: a) the total equity investment at risk is not sufficient to permit the entity to finance its activities without additional subordinated financial support provided by any parties, including equity holders or b) as a group the holders of the equity investment at risk lack any one of the following three characteristics: (i) the power, through voting rights or similar rights to direct the activities of an entity that most significantly impact the entity’s economic performance, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity. The Company reviewed the consolidation guidance and concluded that its partnership interest in Apio Cooling and its equity investments in non-public companies are not VIEs.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. The accounting estimates that require management’s most significant and subjective judgments include revenue recognition; sales returns and allowances; recognition and measurement of current and deferred income tax assets and liabilities; the assessment of recoverability of long-lived assets; the valuation of intangible assets and inventory; the valuation of investments; and the valuation and recognition of stock-based compensation.

These estimates involve the consideration of complex factors and require management to make judgments. The analysis of historical and future trends can require extended periods of time to resolve and is subject to change from period to period. The actual results may differ from management’s estimates.

Cash and Cash Equivalents

The Company records all highly liquid securities with three months or less from date of purchase to maturity as cash equivalents. Cash equivalents consisted of money market funds of $1.5 million at both August 31, 2014 and May 25, 2014. The market value of cash equivalents approximates their historical cost given their short-term nature.

Financial Instruments

The Company’s financial instruments are primarily composed of marketable securities, commercial-term trade payables, grower advances, notes receivable and debt instruments. For short-term instruments, the historical carrying amount approximates the fair value of the instrument. The fair value of long-term debt and lines of credit approximates their carrying value. Fair values for long-term financial instruments not readily marketable are estimated based upon discounted future cash flows at prevailing market interest rates. Based on these assumptions, management believes the fair market values of the Company’s financial instruments are not materially different from their recorded amounts as of August 31, 2014 and May 25, 2014.

Investments in Non-Public Companies

The Company’s investment in Aesthetic Sciences Corporation (“Aesthetic Sciences”), which is reported as an investment in non-public company, non-fair value, in the accompanying Consolidated Balance Sheets, is carried at cost and adjusted for impairment losses. Since there is no readily available market value information, the Company periodically reviews this investment to determine if any other than temporary declines in value have occurred based on the financial stability and viability of Aesthetic Sciences.

On February 15, 2011, Apio purchased 150,000 senior preferred shares for $15 million and 201 common shares for $201 that were issued by Windset Holdings 2010 Ltd., a Canadian corporation (“Windset”), and on July 15, 2014, Apio increased its investment in Windset by purchasing an additional 68 shares of common stock and 15,857 shares of junior preferred stock of Windset for $11.0 million. These investments are reported as an investment in non-public company, fair value, in the accompanying Consolidated Balance Sheets as of August 31, 2014 and May 25, 2014. The Company has elected to account for its investment in Windset under the fair value option (see Note 2).

Intangible Assets

The Company’s intangible assets are comprised of customer relationships with a finite estimated useful life of twelve to thirteen years and trademarks, trade names and goodwill with indefinite lives.

Finite-lived intangible assets are reviewed for possible impairment whenever events or changes in circumstances occur that indicate that the carrying amount of an asset (or asset group) may not be recoverable. Indefinite lived intangible assets are reviewed for impairment at least annually, in accordance with accounting guidance. For non-goodwill indefinite-lived intangible assets, the Company performs a qualitative analysis in accordance with ASC 350-30-35. For goodwill, the Company performs a quantitative analysis in accordance with ASC 350-20-35.

Partial Self-Insurance on Employee Health Plan

The Company provides health insurance benefits to eligible employees under a self-insured plan whereby the Company pays actual medical claims subject to certain stop loss limits. The Company records self-insurance liabilities based on actual claims filed and an estimate of those claims incurred but not reported. Any projection of losses concerning the Company's liability is subject to a high degree of variability. Among the causes of this variability are unpredictable external factors such as inflation rates, changes in severity, benefit level changes, medical costs, and claims settlement patterns. This self-insurance liability is included in accrued liabilities and represents management's best estimate of the amounts that have not been paid as of August 31, 2014 and May 25, 2014. It is reasonably possible that the expense the Company ultimately incurs could differ and adjustments to future reserves may be necessary.

Long-Term Incentive Plan

On July 25, 2013, the Landec Long-Term Incentive Plan (“LTIP”) was established which allows certain executives to earn a performance-based bonus that is based upon a cumulative operating income target for fiscal years 2014, 2015, and 2016. The LTIP was designed to align the interests of management with the long-term financial success of the Company. If the three-year cumulative operating income target is met, approximately $2.0 million in bonuses will be paid. The Company was recording the estimated plan bonus on a straight-line basis over the 36-month LTIP period. As of August 31, 2014, the Company determined it is unlikely the three-year cumulative operating income target will be obtained and therefore all LTIP bonuses were reversed. The reversal resulted in a $677,000 reduction in selling, general, and administrative expenses during the three months ended August 31, 2014 in the accompanying Consolidated Statements of Comprehensive Income. The long-term incentive bonuses accrued under this plan of $0 and $677,000 are included in other non-current liabilities in the accompanying Consolidated Balance Sheets as of August 31, 2014 and May 25, 2014, respectively.

Fair Value Measurements

The Company uses fair value measurement accounting for financial assets and liabilities and for financial instruments and certain other items measured at fair value. The Company has elected the fair value option for its investment in a non-public company (see Note 2). The Company has not elected the fair value option for any of its other eligible financial assets or liabilities.

The accounting guidance established a three-tier hierarchy for fair value measurements, which prioritizes the inputs used in measuring fair value as follows:

Level 1 – observable inputs such as quoted prices for identical instruments in active markets.

Level 2 – inputs other than quoted prices in active markets that are observable either directly or indirectly through corroboration with observable market data.

Level 3 – unobservable inputs in which there is little or no market data, which would require the Company to develop its own assumptions.

As of August 31, 2014, the Company held certain assets and liabilities that are required to be measured at fair value on a recurring basis, including an interest rate swap and a minority interest investment in Windset.

The fair value of the Company’s interest rate swap is determined based on model inputs that can be observed in a liquid market, including yield curves, and is categorized as a Level 2 measurement.

The Company has elected the fair value option of accounting for its investment in Windset. The calculation of fair value utilizes significant unobservable inputs in the discounted cash flow models, including projected cash flows, growth rates and discount rates. As a result, the Company’s investment in Windset is considered to be a Level 3 measurement investment. The change in the fair market value of the Company’s investment in Windset for the three months ended August 31, 2014 was due to the Company’s 26.9% minority interest in the change in the fair market value of Windset during the period. In determining the fair value of the investment in Windset, the Company utilizes the following significant unobservable inputs in the discounted cash flow models:

	At August 31, 2014		At May 25, 2014
Revenue growth rates		4%		4%
Expense growth rates		4%		4%
Income tax rates		15%		15%
Discount rates		16% to 22%		16% to 22%

The revenue growth, expense growth and income tax rate assumptions, consider the Company's best estimate of the trends in those items over the discount period. The discount rate assumption takes into account the risk-free rate of return, the market equity risk premium and the company’s specific risk premium and then applies an additional discount for lack of liquidity of the underlying securities. The discounted cash flow valuation model used by the Company has the following sensitivity to changes in inputs and assumptions (in thousands):

	Impact on value of Windset investment as of August 31, 2014
10% increase in revenue growth rates	$	4,000
10% increase in expense growth rates	$	(3,300	)
10% increase in income tax rates	$	—
10% increase in discount rates	$	(1,800	)

Imprecision in estimating unobservable market inputs can affect the amount of gain or loss recorded for a particular position. The use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

The following table summarizes the fair value of the Company’s assets and liabilities that are measured at fair value on a recurring basis, as of August 31, 2014 and May 25, 2014 (in thousands):

	Fair Value at August 31, 2014						Fair Value at May 25, 2014
Assets:	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Investment in private company		-		-		50,800		-		-		39,600
Total	$	-	$	-	$	50,800	$	-	$	-	$	39,600

Liabilities:
Interest rate swap		-		20		-		-		44		-
Total	$	-	$	20	$	-	$	-	$	44	$	-

Revenue Recognition

Revenue from product sales is recognized when there is persuasive evidence that an arrangement exists, title has transferred, the price is fixed and determinable, and collectability is reasonably assured. Allowances are established for estimated uncollectible amounts, product returns, and discounts based on specific identification and historical losses.

Apio’s Food Products Technology revenues generally consist of revenues generated from the sale of specialty packaged fresh-cut and whole value-added processed vegetable products that are generally washed and packaged in the Company’s proprietary packaging and sold under Apio’s Eat Smart and GreenLine brands and various private labels. Revenue is generally recognized upon shipment of these products to customers. The Company takes title to all produce it trades and/or packages, and therefore, records revenues and cost of sales at gross amounts in the Consolidated Statements of Comprehensive Income

In addition, Food Products Technology value-added revenues include the revenues generated from Apio Cooling, LP, a vegetable cooling operation in which Apio is the general partner with a 60% ownership position and from the sale of BreatheWay packaging to license partners. Revenue is recognized on the vegetable cooling operations as cooling and storage services are provided to the Company’s customers. Sales of BreatheWay packaging are recognized when shipped to the customer.

Apio’s Food Export revenues consist of revenues generated from the purchase and sale of primarily whole commodity fruit and vegetable products to Asia by Cal-Ex. As most Cal-Ex customers are in countries outside of the U.S., title transfers and revenue is generally recognized upon arrival of the shipment in the foreign port. Apio records revenue equal to the sale price to third parties because it takes title to the product while in transit.

The HA-based Biomaterials business principally generates revenue through the sale of products containing HA. Lifecore primarily sells products to customers in three medical areas: (1) Ophthalmic, which represented approximately 60% of Lifecore’s revenues in fiscal year 2014, (2) Orthopedic, which represented approximately 20% of Lifecore’s revenues in fiscal year 2014 and (3) Veterinary/Other. The vast majority of revenues from our HA-based Biomaterials business are recognized upon shipment.

A small amount of revenues from the HA-based Biomaterials business is related to contract research and development (R&D) services and multi-element arrangement services with customers where the Company provides products and/or services in a bundled arrangement.

Contract R&D revenue is recorded as earned, based on the performance requirements of the contract. Non-refundable contract fees for which no further performance obligations exist, and there is no continuing involvement by the Company, are recognized on the earlier of when the payments are received or when collection is assured.

For sales arrangements that contain multiple elements, the Company splits the arrangement into separate units of accounting if the individually delivered elements have value to the customer on a standalone basis. The Company also evaluates whether multiple transactions with the same customer or related party should be considered part of a multiple element arrangement, whereby the Company assesses, among other factors, whether the contracts or agreements are negotiated or executed within a short time frame of each other or if there are indicators that the contracts are negotiated in contemplation of each other. The Company then allocates revenue to each element based on a selling price hierarchy. The relative selling price for a deliverable is based on its vendor-specific objective evidence (VSOE), if available, third-party evidence (TPE), if VSOE is not available, or estimated selling price, if neither VSOE nor TPE is available. The Company then recognizes revenue on each deliverable in accordance with its policies for product and service revenue recognition. The Company is not typically able to determine VSOE or TPE, and therefore, uses estimated selling prices to allocate revenue between the elements of the arrangement.

The Company limits the amount of revenue recognition for delivered elements to the amount that is not contingent on the future delivery of products or services or future performance obligations or subject to customer-specific cancellation rights. The Company evaluates each deliverable in an arrangement to determine whether they represent separate units of accounting. A deliverable constitutes a separate unit of accounting when it has stand-alone value, and for an arrangement that includes a general right of return relative to the delivered products or services, delivery or performance of the undelivered product or service is considered probable and is substantially controlled by the Company. The Company considers a deliverable to have stand-alone value if the product or service is sold separately by the Company or another vendor or could be resold by the customer. Further, the revenue arrangements generally do not include a general right of return relative to the delivered products. Where the aforementioned criteria for a separate unit of accounting are not met, the deliverable is combined with the undelivered element(s) and treated as a single unit of accounting for the purposes of allocation of the arrangement consideration and revenue recognition. The Company allocates the total arrangement consideration to each separable element of an arrangement based upon the relative selling price of each element. Allocation of the consideration is determined at arrangement inception on the basis of each unit’s relative selling price. In instances where the Company has not established fair value for any undelivered element, revenue for all elements is deferred until delivery of the final element is completed and all recognition criteria are met.

Licensing revenue is recognized in accordance with prevailing accounting guidance. Initial license fees are deferred and amortized to revenue over the period of the agreement when a contract exists, the fee is fixed and determinable, and collectability is reasonably assured. Noncancellable, nonrefundable license fees are recognized over the period of the agreement, including those governing research and development activities and any related supply agreement entered into concurrently with the license when the risk associated with commercialization of a product is non-substantive at the outset of the arrangement.

From time to time, the Company offers customers sales incentives, which include volume rebates and discounts. These amounts are estimated on a quarterly basis and recorded as a reduction of revenue.

A summary of revenues by type of revenue arrangement as described above is as follows (in thousands):

	Three months ended August 31, 2014		Three months ended August 25, 2013
Recorded upon shipment	$	106,240	$	87,410
Recorded upon acceptance in foreign port		26,587		21,389
Revenue from license fees, R&D contracts and royalties/profit sharing		212		58
Revenue from multiple element arrangements		575		622
TOTAL	$	133,614	$	109,479

New Accounting Pronouncements

Revenue Recognition

In May 2014, the FASB issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09"), which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The standard requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new guidance also includes a cohesive set of disclosure requirements intended to provide users of financial statements with comprehensive information about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a company’s contracts with customers. ASU 2014-09 will be effective beginning the first quarter of the Company's fiscal year 2018 and early application is not permitted. The standard allows for either “full retrospective” adoption, meaning the standard is applied to all of the periods presented, or “modified retrospective” adoption, meaning the standard is applied only to the most current period presented in the financial statements. Management is currently evaluating the effect ASU 2014-09 will have on the Company's Consolidated Financial Statements and disclosures.

Note 2 - Investments in Non-public Companies

3 Months Ended

Aug. 31, 2014

Investment Holdings [Text Block] [Abstract]

Investment Holdings [Text Block]

2.	Investments in non-public companies

In December 2005, Landec entered into a licensing agreement with Aesthetic Sciences for the exclusive rights to use Landec's Intelimer® materials technology for the development of dermal fillers worldwide under the agreement. The Company received shares of preferred stock in exchange for the license with a valuation of $1.8 million. Aesthetic Sciences sold the rights to its Smartfil™ Injector System on July 16, 2010. Landec has evaluated its investment in Aesthetic Sciences for impairment, utilizing a discounted cash flow analysis under the terms of the purchase agreement. Based on the terms of the sale, the Company determined that its investment was other than temporarily impaired and therefore, recorded an impairment charge of $1.0 million as of May 30, 2010. The Company’s carrying value of its investment in Aesthetic Sciences is $793,000 as of August 31, 2014 and May 25, 2014. No additional impairment has been determined for the Company’s investment in Aesthetic Sciences.

On February 15, 2011, Apio entered into a share purchase agreement (the “Windset Purchase Agreement”) with Windset. Pursuant to the Windset Purchase Agreement, Apio purchased from Windset 150,000 senior preferred shares for $15 million and 201 common shares for $201. On July 15, 2014, Apio increased its investment in Windset by purchasing from the Newell Capital Corporation an additional 68 shares of common stock and 15,857 shares of junior preferred stock of Windset for $11.0 million. After this purchase, the Company’s common shares represent a 26.9% interest in Windset. The non-voting senior preferred shares yield a cash dividend of 7.5% annually. The dividend is payable within 90 days of each anniversary of the execution of the Windset Purchase Agreement The non-voting junior preferred stock does not yield a dividend unless declared by the Board of Directors of Windset and no such dividend has been declared.

The Windset Purchase Agreement includes a put and call option, which can be exercised on the sixth anniversary of the Windset Purchase Agreement whereby Apio can exercise the put to sell its common and preferred shares to Windset, or Windset can exercise the call to purchase the those shares from Apio, in either case, at a price equal to 26.9% of the appreciation in the fair market value of Windset’s common shares from the date of the Company’s investment through the put and call date, plus the liquidation value of the preferred shares of $20.1 million ($15 million for the senior preferred shares and $5.1 million for the junior preferred shares). Under the terms of the arrangement with Windset, the Company is entitled to designate one of five members on the Board of Directors of Windset.

The investment in Windset does not qualify for equity method accounting as the investment does not meet the criteria of in-substance common stock due to returns through the annual dividend on the non-voting senior preferred shares that are not available to the common stock holders. As the put and call options require the Purchased Shares to be put or called in equal proportions, the Company has deemed that the investment, in substance, should be treated as a single security for purposes of accounting. The Company has adopted fair value option in the accounting for its investment in Windset effective on the acquisition date. The fair value of the Company’s investment in Windset utilizes significant unobservable inputs in the discounted cash flow models, including projected cash flows, revenue/expense growth rates and discount rates (see Note 1) and is therefore considered a Level 3 investment for fair value measurement purposes. The Company believes that reporting its investment at fair value provides its investors with useful information on the performance of the Company’s investment and the anticipated appreciation in value as Windset expands its business.

The fair value of the Company’s investment in Windset was determined utilizing a discounted cash flow model based on projections developed by Windset, and considers the put and call conversion options. These features impact the duration of the cash flow utilized to derive the estimated fair value of the investment. Assumptions included in the discounted cash flow model will be evaluated quarterly based on Windset’s actual and projected operating results to determine the change in fair value.

During both the three months ended August 31, 2014 and August 25, 2013, the Company recorded $281,000 in dividend income. The change in the fair market value of the Company’s investment in Windset for the three months ended August 31, 2014 and August 25, 2013 was $200,000 and $5.4 million, respectively, and is included in other income in the Consolidated Statements of Comprehensive Income.

The Company also entered into an exclusive license agreement with Windset, which was executed in June 2010, prior to contemplation of Apio’s investment in Windset. The license agreement allows Windset the use of Landec’s proprietary breathable packaging to extend the shelf life of greenhouse grown cucumbers, peppers and tomatoes (“Exclusive Products”). In accordance with the agreement, Apio received and recorded a one-time upfront research and development fee of $100,000 and will receive license fees equal to 3% of net revenue of the Exclusive Products utilizing the proprietary breathable packaging technology, with or without the BreatheWay® trademark. The ongoing license fees are subject to annual minimums of $150,000 for each of the three types of exclusive product as each is added to the agreement. As of August 31, 2014, two products have been added to the agreement.

Note 3 - Stock-Based Compensation

3 Months Ended

Aug. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

3.	Stock-Based Compensation

The Company records compensation expense for stock-based awards issued to employees and directors in exchange for services provided based on the estimated fair value of the awards on their grant dates and is recognized over the required service periods (generally the vesting period). For nonstatutory options, the cash flows resulting from the tax benefit due to tax deductions in excess of the compensation expense recognized for those options (excess tax benefit) are classified as financing activities within the statement of cash flows. The Company’s stock-based awards include stock option grants and restricted stock unit awards (“RSUs”).

The following table summarizes the stock-based compensation for options and RSUs (in thousands):

	Three Months Ended August 31, 2014		Three Months Ended August 25, 2013
Options	$	133	$	108
RSUs		265		170
Total stock-based compensation expense	$	398	$	278

The following table summarizes the stock-based compensation by income statement line item (in thousands):

	Three Months Ended August 31, 2014		Three Months Ended August 25, 2013
Research and development	$	12	$	14
Sales, general and administrative		386		264
Total stock-based compensation expense	$	398	$	278

The estimated fair value for stock options, which determines the Company’s calculation of compensation expense, is based on the Black-Scholes option pricing model. RSUs are valued at the closing market price of the Company’s common stock on the date of grant. The Company uses the straight line single option method to calculate and recognize the fair value of stock-based compensation arrangements. In addition, the Company uses historical data to estimate pre-vesting forfeitures and records stock-based compensation expense only for those awards that are expected to vest and revises those estimates in subsequent periods if the actual forfeitures differ from the prior estimates.

As of August 31, 2014, there was $2.2 million of total unrecognized compensation expense related to unvested equity compensation awards granted under the Landec incentive stock plans. Total expense is expected to be recognized over the weighted-average period of 1.8 years for stock options and 1.6 years for restricted stock unit awards.

Note 4 - Diluted Net Income Per Share

3 Months Ended

Aug. 31, 2014

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

4.	Diluted Net Income Per Share

The following table sets forth the computation of diluted net income per share (in thousands, except per share amounts):

	Three Months Ended August 31, 2014		Three Months Ended August 25, 2013
Numerator:
Net income applicable to Common Stockholders	$	2,353	$	4,752

Denominator:
Weighted average shares for basic net income per share		26,840		26,452
Effect of dilutive securities:
Stock options and restricted stock units		427		629
Weighted average shares for diluted net income per share		27,267		27,081

Diluted net income per share	$	0.09	$	0.18

For the three months ended August 31, 2014 and August 25, 2013, the computation of the diluted net income per share excludes the impact of options to purchase 336,071 shares and 256,264 shares of Common Stock, respectively, as such impacts would be antidilutive for these periods.

Note 5 - Income Taxes

3 Months Ended

Aug. 31, 2014

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

5.	Income Taxes

The provision for income taxes for the three months ended August 31, 2014 was $1.3 million. The effective tax rate for the three months ended August 31, 2014 was 36%, compared to 34% for the first quarter of fiscal year 2014. The effective tax rate for the three months ended August 31, 2014 was higher than the statutory federal income tax rate of 35% due to several factors, including state taxes, domestic manufacturing deductions, non-deductible stock-based compensation expense and the benefit of federal and state research and development credits.

As of August 31, 2014 and May 25, 2014, the Company had unrecognized tax benefits of approximately $1.1 million and $1.0 million, respectively. Included in the balance of unrecognized tax benefits as of August 31, 2014 and May 25, 2014 is approximately $850,000 and $817,000, respectively, of tax benefits that, if recognized, would result in an adjustment to the Company’s effective tax rate. The Company does not expect its unrecognized tax benefits to change significantly within the next twelve months.

The Company has elected to classify interest and penalties related to uncertain tax positions as a component of its provision for income taxes. The Company has accrued an insignificant amount of interest and penalties relating to the income tax on the unrecognized tax benefits as of August 31, 2014 and May 25, 2014.

Due to tax attribute carryforwards, the Company is subject to examination for tax years 1997 forward for U.S. tax purposes. The Company is also subject to examination in various state jurisdictions for tax years 1998 forward, none of which were individually material.

Note 6 - Inventories

3 Months Ended

Aug. 31, 2014

Inventory Disclosure [Abstract]

Inventory Disclosure [Text Block]

6.	Inventories

Inventories are stated at the lower of cost (first-in, first-out method) or market and consisted of the following (in thousands):

	August 31, 2014		May 25, 2014
Finished goods	$	14,139	$	11,111
Raw materials		10,620		10,376
Work in progress		3,075		3,248
Total	$	27,834	$	24,735

Note 7 - Debt

3 Months Ended

Aug. 31, 2014

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

Debt

Long-term debt consists of the following (in thousands):

	August 31, 2014			May 25, 2014
Real estate loan agreement with General Electric Capital Corporation (“GE Capital”); due in monthly principal and interest payments of $133,060 through May 1, 2022 with interest based on a fixed rate of 4.02% per annum	$	15,900		$	16,137
Capital equipment loan with GE Capital; due in monthly principal and interest payments of $175,356 through May 1, 2019 with interest based on a fixed rate of 4.39% per annum		9,006			9,430
Capital equipment loan with GE Capital; due in monthly principal and interest payments of $95,120 through July 17, 2019 with interest based on a fixed rate of 3.68% per annum		7,070			—
Term note with BMO Harris Bank N.A. (“BMO Harris”); due in monthly payments of $250,000 through May 23, 2016 with interest payable monthly at LIBOR plus 2% per annum		5,250			6,000
Industrial revenue bonds (“IRBs”) issued by Lifecore; due in annual payments through 2020 with interest at a variable rate set weekly by the bond remarketing agent (0.25% and 0.28% at August 31, 2014 and May 25, 2014, respectively)		2,805			2,805
Total		40,031			34,372
Less current portion		(6,980	)		(6,055	)
Long-term portion	$	33,051		$	28,317

On July 17, 2014, Apio entered into an amendment with GE Capital, which amended the revolving line of credit dated April 23, 2012 among the parties. Under the amendment, the revolving line of credit increased from $25 million to $40 million, the interest rate was reduced from LIBOR plus 2.0% to LIBOR plus 1.75%, the term was extended to July 17, 2019 and the parties made certain other insignificant changes. The availability under the revolving line of credit is based on the combination of the eligible accounts receivable and eligible inventory (availability was $27.5 million at August 31, 2014). Apio’s revolving line of credit has an unused fee of 0.375% per annum. At August 31, 2014 and May 25, 2014, no amounts were outstanding under Apio’s revolving line of credit.

Also on July 17, 2014, Apio entered into a new equipment loan whereby Apio can borrow up to $25 million based on eligible equipment purchases between August 1, 2012 and August 31, 2015. Each borrowing under this new equipment loan has a five year term with a seven year amortization period at a fixed rate of 3.68%. During the three months ended August 31, 2014, Apio borrowed $7.1 million under this new equipment loan.

During the three months ended August 31, 2014, Apio capitalized $226,000 of loan origination fees from the revolving line of credit amendment and from the new equipment loan with GE Capital. These fees are being amortized over a five year period. Unamortized loan origination fees associated with all of the GE Capital debt agreements were $1.1 million and $1.0 million at August 31, 2014 and May 25, 2014, respectively, and are included in other assets in the Consolidated Balance Sheets.

Amortization of loan origination fees for Apio recorded to interest expense for the three months ended August 31, 2014 and August 25, 2013 were $46,000 and $47,000, respectively.

On May 23, 2012, Lifecore entered into two financing agreements with BMO Harris and/or its affiliates, collectively (the “Lifecore Loan Agreements”):

A Credit and Security Agreement (the “Credit Agreement”) which includes (a) a one-year, $10.0 million asset-based working capital revolving line of credit, with an interest rate of LIBOR plus 1.85%, with availability based on the combination of Lifecore’s eligible accounts receivable and inventory balances (availability was $7.7 million at August 31, 2014) and with no unused fee (at August 31, 2014 and May 25, 2014, no amounts were outstanding under the line of credit) and (b) a $12.0 million term loan which matures in four years due in monthly payments of $250,000 with interest payable monthly based on a variable interest rate of LIBOR plus 2% (the “Term Loan”).

A Reimbursement Agreement pursuant to which BMO Harris caused its affiliate Bank of Montreal to issue an irrevocable letter of credit in the amount of $3.5 million (the “Letter of Credit”) which is securing the IRB described below.

The obligations of Lifecore under the Lifecore Loan Agreements are secured by liens on all of the property of Lifecore. The Lifecore Loan Agreements contain customary covenants, such as limitations on the ability to (1) incur

indebtedness or grant liens or negative pledges on Lifecore’s assets; (2) make loans or other investments; (3) pay dividends or repurchase stock or other securities; (4) sell assets; (5) engage in mergers; (6) enter into sale and leaseback transactions; (7) adopt certain benefit plans; and (8) make changes in Lifecore’s corporate structure. In addition, under the Credit Agreement, Lifecore must maintain (a) a minimum fixed charge coverage ratio of 1.10 to 1.0 and a minimum quick ratio of 1.25 to 1.00, both of which must be satisfied as of the end of each fiscal quarter and (b) a minimum tangible net worth of $29,000,000, measured as of the end of each fiscal year. Lifecore was in compliance with all financial covenants as of August 31, 2014 and May 25, 2014. Unamortized loan origination fees for the Lifecore Loan Agreements were $86,000 and $98,000 at August 31, 2014 and May 25, 2014, respectively, and are included in other assets in the Consolidated Balance Sheets. Amortization of loan origination fees recorded to interest expense for both three months ended August 31, 2014 and August 25, 2013 was $13,000.

The market value of the Company’s debt approximates its recorded value as the interest rate on each debt instrument approximates current market rates.

The Term Loan was used to repay Lifecore’s former credit facility with Wells Fargo Bank, N.A. (“Wells Fargo”). The Letter of Credit (which replaces a letter of credit previously provided by Wells Fargo) provides liquidity and credit support for the IRBs.

On August 19, 2004, Lifecore issued variable rate industrial revenue bonds (“IRBs”) which were assumed by Landec in the acquisition of Lifecore. The IRBs are collateralized by a bank letter of credit which is secured by a first mortgage on the Company’s facility in Chaska, Minnesota. In addition, the Company pays an annual remarketing fee equal to 0.125% and an annual letter of credit fee of 0.75%. The maturities on the IRBs are held in a sinking fund account, recorded in other assets in the accompanying Consolidated Balance Sheets, and are paid out each year on September 1^st.

Note 8 - Derivative Financial Instruments

3 Months Ended

Aug. 31, 2014

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]

8.	Derivative Financial Instruments

In May 2010, the Company entered into a five-year interest rate swap agreement under its prior credit agreement with Wells Fargo, which expires on April 30, 2015. The interest rate swap was originally designated as a cash flow hedge of future interest payments of LIBOR and had a notional amount of $20 million. As a result of the interest rate swap transaction, the Company fixed for a five-year period the interest rate at 4.24% subject to market based interest rate risk on $20 million of borrowings under the credit agreement with Wells Fargo. The Company’s obligations under the interest rate swap transaction as to the scheduled payments were guaranteed and secured on the same basis as its obligations under the credit agreement with Wells Fargo at the time the agreement was consummated. Upon entering into the new Term Loan with BMO Harris, the Company used the proceeds from that loan to pay off the Wells Fargo credit facility. The swap with Wells Fargo was not terminated upon the extinguishment of the debt with Wells Fargo. The fair value of the swap arrangement as of August 31, 2014 and May 25, 2014 was $20,000 and $44,000, respectively, and is included in other accrued liabilities in the accompanying Consolidated Balance Sheets.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Note 9 - Related Party

3 Months Ended

Aug. 31, 2014

9.	Related Party

The Company sells products to and earns license fees from Windset. During the three months ended August 31, 2014 and August 25, 2013, the Company recognized revenues of $34,000 and $32,000, respectively, which have been included in product sales in the accompanying Consolidated Statements of Comprehensive Income, from the sale of products to and license fees from Windset. The related receivable balances of $338,000 and $304,000 are included in accounts receivable, related party, in the accompanying Consolidated Balance Sheets as of August 31, 2014 and May 25, 2014, respectively.

Additionally, unrelated to the revenue transactions above, the Company purchases produce from Windset for sale to third parties. During the three months ended August 31, 2014 and August 25, 2013, the Company recognized cost of product sales of $411,000 and $364,000, respectively, which have been included in cost of product sales in the accompanying Consolidated Statements of Comprehensive Income, from the sale of products purchased from Windset. The related accounts payable of $167,000 and $134,000 are included in accounts payable, related party in the accompanying Consolidated Balance Sheets as of August 31, 2014 and May 25, 2014, respectively.

All related party transactions are monitored quarterly by the Company and approved by the Audit Committee of the Board of Directors.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Note 10 - Stockholders' Equity

3 Months Ended

Aug. 31, 2014

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

10.

Stockholders’ Equity

During the three months ended August 31, 2014, the Company granted options to purchase 469 shares of common stock and 29,496 of restricted stock unit awards.

As of August 31, 2014 the Company has reserved 3.1 million shares of Common Stock for future issuance under its current and former equity plans.

On July 14, 2010, the Company announced that the Board of Directors of the Company had approved the establishment of a stock repurchase plan authorizing the repurchase of up to $10 million of the Company’s Common Stock. The Company may repurchase its common stock from time to time in open market purchases or in privately negotiated transactions. The timing and actual number of shares repurchased is at the discretion of management of the Company and will depend on a variety of factors, including stock price, corporate and regulatory requirements, market conditions, the relative attractiveness of other capital deployment opportunities and other corporate priorities. The stock repurchase program does not obligate Landec to acquire any amount of its common stock and the program may be modified, suspended or terminated at any time at the Company's discretion without prior notice. During the three months ended August 31, 2014, the Company did not purchase any shares on the open market.

Consolidated Statements of Changes in Stockholders’ Equity (in thousands, except share amounts):

	August 31, 2014
Common Stock Shares
Balance at May 25, 2014		26,815,253
Stock options exercised, net of shares tendered		469
Vested restricted stock units, net of shares tendered		29,496
Balance at August 31, 2014		26,845,218

Common Stock
Balance at May 25, 2014	$	27
Stock options exercised, net of shares tendered		—
Vested restricted stock units, net of shares tendered		—
Balance at August 31, 2014	$	27

Additional Paid-in Capital
Balance at May 25, 2014	$	131,488
Stock options exercised, net of shares tendered		3
Vested restricted stock units, net of shares tendered		—
Taxes paid by Company for stock swaps and RSUs		(12	)
Stock-based compensation expense		398
Tax from stock based compensation expense		(44	)
Balance at August 31, 2014	$	131,833

Retained Earnings
Balance at May 25, 2014	$	71,554
Net income		2,353
Balance at August 31, 2014	$	73,907

Non controlling Interest
Balance at May 25, 2014	$	1,692
Non controlling interest in net income		71
Distributions to non controlling interest		—
Balance at August 31, 2014	$	1,763

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Note 11 - Business Segment Reporting

3 Months Ended

Aug. 31, 2014

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

11.	Business Segment Reporting

The Company manages its business operations through three strategic business units. Based upon the information reported to the chief operating decision maker, who is the Chief Executive Officer, the Company has the following reportable segments: the Food Products Technology segment, the Food Export segment and the Hyaluronan-based Biomaterials segment.

The Food Products Technology segment markets and packs specialty packaged whole and fresh-cut fruit and vegetables, the majority of which incorporate the BreatheWay specialty packaging for the retail grocery, club store and food services industry. In addition, the Food Products Technology segment sells BreatheWay packaging to partners for non-vegetable products. The Food Export segment consists of revenues generated from the purchase and sale of primarily whole commodity fruit and vegetable products to Asia and domestically. The HA-based Biomaterials segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans, for medical use primarily in the Ophthalmic, Orthopedic and Veterinary markets. Corporate licenses Landec’s patented Intellicoat seed coatings to the farming industry and licenses the Company’s Intelimer polymers for personal care products and other industrial products. The Corporate segment also includes general and administrative expenses, non-Food Products Technology and non HA-based Biomaterials interest income and income tax expenses. All of the assets of the Company are located within the United States of America.

The Company’s international sales were as follows (in millions):

	Three Months Ended
	August 31, 2014		August 25, 2013
Canada	$	17.7	$	9.4
Taiwan	$	16.2	$	12.0
China	$	4.4	$	1.6
Japan	$	2.8	$	3.2
Indonesia	$	1.6	$	2.5
Belgium	$	—	$	1.2
All Other Countries	$	3.7	$	5.3

Operations and identifiable assets by business segment consisted of the following (in thousands):

Three Months Ended August 31, 2014	Food Products Technology		Food Export		HA-based Biomaterials			Corporate			TOTAL
Net sales	$	100,106	$	26,597	$	6,811		$	100		$	133,614
International sales	$	18,151	$	26,587	$	1,634		$	—		$	46,372
Gross profit	$	11,854	$	1,186	$	1,048		$	100		$	14,188
Net income (loss)	$	3,646	$	271	$	(1,542	)	$	(22	)	$	2,353
Depreciation and amortization	$	1,010	$	1	$	471		$	31		$	1,513
Dividend Income	$	281	$	—	$	—		$	—		$	281
Interest income	$	11	$	—	$	71		$	11		$	93
Interest expense	$	338	$	—	$	45		$	—		$	383
Income tax expense (benefit)	$	870	$	44	$	(251	)	$	638		$	1,301

Three Months Ended August 25, 2013
Net sales	$	79,436	$	21,398	$	8,587		$	58		$	109,479
International sales	$	9,478	$	21,389	$	4,377		$	—		$	35,244
Gross profit	$	8,881	$	1,205	$	2,388		$	58		$	12,532
Net income (loss)	$	7,266	$	276	$	(376	)	$	(2,414	)	$	4,752
Depreciation and amortization	$	1,222	$	1	$	584		$	35		$	1,842
Dividend Income	$	281	$	—	$	—		$	—		$	281
Interest income	$	4	$	—	$	56		$	—		$	60
Interest expense	$	376	$	—	$	55		$	—		$	431
Income tax expense (benefit)	$	505	$	78	$	(106	)	$	1,998		$	2,475

During the three months ended August 31, 2014 and August 25, 2013, sales to the Company’s top five customers accounted for 46% and 44%, respectively, of revenues. The Company’s top two customers, Costco Wholesale Corporation and Wal-Mart Stores, Inc., from the Food Products Technology segment accounted for 20% and 11% of revenues, respectively, for the three months ended August 31, 2014 and 20% and 12% of revenues, respectively, for the three months ended August 25, 2013. The Company expects that, for the foreseeable future, a limited number of customers may continue to account for a significant portion of its net revenues.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

+ Details

Accounting Policies, by Policy (Policies)

3 Months Ended

Aug. 31, 2014

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

Consolidation, Policy [Policy Text Block]

Basis of Consolidation

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

Fair Value of Financial Instruments, Policy [Policy Text Block]

Financial Instruments

Investment In Non-Public Companies [Policy Text Block]

Investments in Non-Public Companies

Goodwill and Intangible Assets, Policy [Policy Text Block]

Intangible Assets

Self Insurance Reserve [Policy Text Block]

Partial Self-Insurance on Employee Health Plan

Long-Term Incentive Plan

Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

The accounting guidance established a three-tier hierarchy for fair value measurements, which prioritizes the inputs used in measuring fair value as follows:

Level 1 – observable inputs such as quoted prices for identical instruments in active markets.

Level 2 – inputs other than quoted prices in active markets that are observable either directly or indirectly through corroboration with observable market data.

Level 3 – unobservable inputs in which there is little or no market data, which would require the Company to develop its own assumptions.

The fair value of the Company’s interest rate swap is determined based on model inputs that can be observed in a liquid market, including yield curves, and is categorized as a Level 2 measurement.

	At August 31, 2014		At May 25, 2014
Revenue growth rates		4%		4%
Expense growth rates		4%		4%
Income tax rates		15%		15%
Discount rates		16% to 22%		16% to 22%

	Impact on value of Windset investment as of August 31, 2014
10% increase in revenue growth rates	$	4,000
10% increase in expense growth rates	$	(3,300	)
10% increase in income tax rates	$	—
10% increase in discount rates	$	(1,800	)

The following table summarizes the fair value of the Company’s assets and liabilities that are measured at fair value on a recurring basis, as of August 31, 2014 and May 25, 2014 (in thousands):

	Fair Value at August 31, 2014						Fair Value at May 25, 2014
Assets:	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Investment in private company		-		-		50,800		-		-		39,600
Total	$	-	$	-	$	50,800	$	-	$	-	$	39,600

Liabilities:
Interest rate swap		-		20		-		-		44		-
Total	$	-	$	20	$	-	$	-	$	44	$	-

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

From time to time, the Company offers customers sales incentives, which include volume rebates and discounts. These amounts are estimated on a quarterly basis and recorded as a reduction of revenue.

A summary of revenues by type of revenue arrangement as described above is as follows (in thousands):

	Three months ended August 31, 2014		Three months ended August 25, 2013
Recorded upon shipment	$	106,240	$	87,410
Recorded upon acceptance in foreign port		26,587		21,389
Revenue from license fees, R&D contracts and royalties/profit sharing		212		58
Revenue from multiple element arrangements		575		622
TOTAL	$	133,614	$	109,479

New Accounting Pronouncements, Policy [Policy Text Block]

New Accounting Pronouncements

Revenue Recognition

Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Aug. 31, 2014

Accounting Policies [Abstract]

Schedule of Effect of Significant Unobservable Inputs for Investment [Table Text Block]

	At August 31, 2014		At May 25, 2014
Revenue growth rates		4%		4%
Expense growth rates		4%		4%
Income tax rates		15%		15%
Discount rates		16% to 22%		16% to 22%

Schedule of Sensitivity Analysis of Fair Value, Transferor's Interests in Transferred Financial Assets [Table Text Block]

	Impact on value of Windset investment as of August 31, 2014
10% increase in revenue growth rates	$	4,000
10% increase in expense growth rates	$	(3,300	)
10% increase in income tax rates	$	—
10% increase in discount rates	$	(1,800	)

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Fair Value at August 31, 2014						Fair Value at May 25, 2014
Assets:	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Investment in private company		-		-		50,800		-		-		39,600
Total	$	-	$	-	$	50,800	$	-	$	-	$	39,600

Liabilities:
Interest rate swap		-		20		-		-		44		-
Total	$	-	$	20	$	-	$	-	$	44	$	-

Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block]

	Three months ended August 31, 2014		Three months ended August 25, 2013
Recorded upon shipment	$	106,240	$	87,410
Recorded upon acceptance in foreign port		26,587		21,389
Revenue from license fees, R&D contracts and royalties/profit sharing		212		58
Revenue from multiple element arrangements		575		622
TOTAL	$	133,614	$	109,479

Note 3 - Stock-Based Compensation (Tables)

3 Months Ended

Aug. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

	Three Months Ended August 31, 2014		Three Months Ended August 25, 2013
Options	$	133	$	108
RSUs		265		170
Total stock-based compensation expense	$	398	$	278

	Three Months Ended August 31, 2014		Three Months Ended August 25, 2013
Research and development	$	12	$	14
Sales, general and administrative		386		264
Total stock-based compensation expense	$	398	$	278

Note 4 - Diluted Net Income Per Share (Tables)

3 Months Ended

Aug. 31, 2014

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended August 31, 2014		Three Months Ended August 25, 2013
Numerator:
Net income applicable to Common Stockholders	$	2,353	$	4,752

Denominator:
Weighted average shares for basic net income per share		26,840		26,452
Effect of dilutive securities:
Stock options and restricted stock units		427		629
Weighted average shares for diluted net income per share		27,267		27,081

Diluted net income per share	$	0.09	$	0.18

Note 6 - Inventories (Tables)

3 Months Ended

Aug. 31, 2014

Inventory Disclosure [Abstract]

Schedule of Inventory, Current [Table Text Block]

	August 31, 2014		May 25, 2014
Finished goods	$	14,139	$	11,111
Raw materials		10,620		10,376
Work in progress		3,075		3,248
Total	$	27,834	$	24,735

Note 7 - Debt (Tables)

3 Months Ended

Aug. 31, 2014

Debt Disclosure [Abstract]

Schedule of Long-term Debt Instruments [Table Text Block]

	August 31, 2014			May 25, 2014
Real estate loan agreement with General Electric Capital Corporation (“GE Capital”); due in monthly principal and interest payments of $133,060 through May 1, 2022 with interest based on a fixed rate of 4.02% per annum	$	15,900		$	16,137
Capital equipment loan with GE Capital; due in monthly principal and interest payments of $175,356 through May 1, 2019 with interest based on a fixed rate of 4.39% per annum		9,006			9,430
Capital equipment loan with GE Capital; due in monthly principal and interest payments of $95,120 through July 17, 2019 with interest based on a fixed rate of 3.68% per annum		7,070			—
Term note with BMO Harris Bank N.A. (“BMO Harris”); due in monthly payments of $250,000 through May 23, 2016 with interest payable monthly at LIBOR plus 2% per annum		5,250			6,000
Industrial revenue bonds (“IRBs”) issued by Lifecore; due in annual payments through 2020 with interest at a variable rate set weekly by the bond remarketing agent (0.25% and 0.28% at August 31, 2014 and May 25, 2014, respectively)		2,805			2,805
Total		40,031			34,372
Less current portion		(6,980	)		(6,055	)
Long-term portion	$	33,051		$	28,317

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5

+ Details

Note 10 - Stockholders' Equity (Tables)

3 Months Ended

Aug. 31, 2014

Stockholders' Equity Note [Abstract]

Schedule of Stockholders Equity [Table Text Block]

	August 31, 2014
Common Stock Shares
Balance at May 25, 2014		26,815,253
Stock options exercised, net of shares tendered		469
Vested restricted stock units, net of shares tendered		29,496
Balance at August 31, 2014		26,845,218

Common Stock
Balance at May 25, 2014	$	27
Stock options exercised, net of shares tendered		—
Vested restricted stock units, net of shares tendered		—
Balance at August 31, 2014	$	27

Additional Paid-in Capital
Balance at May 25, 2014	$	131,488
Stock options exercised, net of shares tendered		3
Vested restricted stock units, net of shares tendered		—
Taxes paid by Company for stock swaps and RSUs		(12	)
Stock-based compensation expense		398
Tax from stock based compensation expense		(44	)
Balance at August 31, 2014	$	131,833

Retained Earnings
Balance at May 25, 2014	$	71,554
Net income		2,353
Balance at August 31, 2014	$	73,907

Non controlling Interest
Balance at May 25, 2014	$	1,692
Non controlling interest in net income		71
Distributions to non controlling interest		—
Balance at August 31, 2014	$	1,763

Note 11 - Business Segment Reporting (Tables)

3 Months Ended

Aug. 31, 2014

Segment Reporting [Abstract]

Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]

	Three Months Ended
	August 31, 2014		August 25, 2013
Canada	$	17.7	$	9.4
Taiwan	$	16.2	$	12.0
China	$	4.4	$	1.6
Japan	$	2.8	$	3.2
Indonesia	$	1.6	$	2.5
Belgium	$	—	$	1.2
All Other Countries	$	3.7	$	5.3

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Three Months Ended August 31, 2014	Food Products Technology		Food Export		HA-based Biomaterials			Corporate			TOTAL
Net sales	$	100,106	$	26,597	$	6,811		$	100		$	133,614
International sales	$	18,151	$	26,587	$	1,634		$	—		$	46,372
Gross profit	$	11,854	$	1,186	$	1,048		$	100		$	14,188
Net income (loss)	$	3,646	$	271	$	(1,542	)	$	(22	)	$	2,353
Depreciation and amortization	$	1,010	$	1	$	471		$	31		$	1,513
Dividend Income	$	281	$	—	$	—		$	—		$	281
Interest income	$	11	$	—	$	71		$	11		$	93
Interest expense	$	338	$	—	$	45		$	—		$	383
Income tax expense (benefit)	$	870	$	44	$	(251	)	$	638		$	1,301

Three Months Ended August 25, 2013
Net sales	$	79,436	$	21,398	$	8,587		$	58		$	109,479
International sales	$	9,478	$	21,389	$	4,377		$	—		$	35,244
Gross profit	$	8,881	$	1,205	$	2,388		$	58		$	12,532
Net income (loss)	$	7,266	$	276	$	(376	)	$	(2,414	)	$	4,752
Depreciation and amortization	$	1,222	$	1	$	584		$	35		$	1,842
Dividend Income	$	281	$	—	$	—		$	—		$	281
Interest income	$	4	$	—	$	56		$	—		$	60
Interest expense	$	376	$	—	$	55		$	—		$	431
Income tax expense (benefit)	$	505	$	78	$	(106	)	$	1,998		$	2,475

Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details)			3 Months Ended	24 Months Ended	37 Months Ended
	Jul. 15, 2014 USD ($) shares	Feb. 15, 2011 USD ($) shares	Aug. 31, 2014 USD ($)	May 25, 2015	Aug. 28, 2016 USD ($)	May 25, 2014 USD ($)
Selling, General and Administrative Expenses [Member] \| Bonus under Long-Term Incentive Plan [Member]
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) [Line Items]
Officers' Compensation			$ (677,000)
HA-based Biomaterials [Member] \| Ophthalmic [Member] \| Sales Revenue, Goods, Net [Member] \| Product Concentration Risk [Member]
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage				60.00%
HA-based Biomaterials [Member] \| Orthopedic [Member] \| Sales Revenue, Goods, Net [Member] \| Product Concentration Risk [Member]
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage			20.00%
HA-based Biomaterials [Member]
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) [Line Items]
Number of Product Segments			3
Scenario, Forecast [Member] \| Bonus under Long-Term Incentive Plan [Member]
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) [Line Items]
Officers' Compensation					$ 2,000,000
Customer Relationships [Member] \| Minimum [Member]
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life			12 years
Customer Relationships [Member] \| Maximum [Member]
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life			13 years
Preferred Stock [Member] \| Windset [Member] \| Apio, Inc [Member]
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) [Line Items]
Investment in Non-Public Company Shares (in Shares) \| shares	15,857
Preferred Stock [Member] \| Windset [Member]
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) [Line Items]
Investment in Non-Public Company Shares (in Shares) \| shares	15,857	150,000
Payments to Acquire Investments		$ 15,000,000
Common Stock [Member] \| Windset [Member] \| Apio, Inc [Member]
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) [Line Items]
Investment in Non-Public Company Shares (in Shares) \| shares	68	201
Payments to Acquire Investments		$ 201
Common Stock [Member] \| Windset [Member]
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) [Line Items]
Investment in Non-Public Company Shares (in Shares) \| shares	68	201
Payments to Acquire Investments		$ 201
Cash and Cash Equivalents [Member]
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) [Line Items]
Money Market Funds, at Carrying Value			$ 1,500,000			$ 1,500,000
Bonus under Long-Term Incentive Plan [Member]
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) [Line Items]
Accrued Bonuses			$ 0			$ 677,000
Windset [Member] \| Apio, Inc [Member]
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) [Line Items]
Payments to Acquire Investments	$ 11,000,000
Windset [Member]
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) [Line Items]
Investment Ownership Percentage	26.90%		26.90%
Apio Cooling, LP [Member] \| Apio, Inc [Member]
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) [Line Items]
Investment Ownership Percentage			60.00%
Number of Proprietary Platforms			2
Payments to Acquire Investments			$ 11,000,000

Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) - Significant Unobservable Inputs Used in Discounted Cash Flow Models	3 Months Ended	12 Months Ended
	Aug. 31, 2014	May 25, 2014
Minimum [Member]
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) - Significant Unobservable Inputs Used in Discounted Cash Flow Models [Line Items]
Discount rates	16.00%	16.00%
Maximum [Member]
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) - Significant Unobservable Inputs Used in Discounted Cash Flow Models [Line Items]
Discount rates	22.00%	22.00%
Revenue growth rates	4.00%	4.00%
Expense growth rates	4.00%	4.00%
Income tax rates	15.00%	15.00%

Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) - Sensitiviy to Changes in Inputs and Assumptions Used in Discounted Cash Flow Models $ in Thousands	Aug. 31, 2014 USD ($)
Sensitiviy to Changes in Inputs and Assumptions Used in Discounted Cash Flow Models [Abstract]
10% increase in revenue growth rates	$ 4,000
10% increase in expense growth rates	(3,300)
10% increase in discount rates	$ (1,800)

Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) - Fair Value of Assets and Liabilities Measure on Recurring Basis - USD ($) $ in Thousands	Aug. 31, 2014	May 25, 2014
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Interest rate swap	$ 20	$ 44
Total	20	44
Fair Value, Inputs, Level 3 [Member]
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) - Fair Value of Assets and Liabilities Measure on Recurring Basis [Line Items]
Investment in private company	50,800	39,600
Total	$ 50,800	$ 39,600

- Definition

Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12.Column C.3,4)
-URI http://asc.fasb.org/extlink&oid=34726532&loc=d3e611133-123010

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-12C.Column C.7)
-URI http://asc.fasb.org/extlink&oid=34726532&loc=d3e611225-123010

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14.Column E.2,3)
-URI http://asc.fasb.org/extlink&oid=34726532&loc=d3e611322-123010

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13.Column C.6)
-URI http://asc.fasb.org/extlink&oid=34726532&loc=d3e611282-123010

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 12
-Paragraph Column C
-Article 12

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 12
-Paragraph 3, 4
-Article 12

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 14
-Paragraph 2, 3
-Article 12

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 13
-Paragraph 6
-Article 12

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 12C
-Paragraph 7
-Article 12

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 14
-Paragraph Column E
-Article 12

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 13
-Paragraph Column C
-Article 12

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 12C
-Paragraph Column C
-Article 12

+ Details

Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Details) - Revenue Arrangements - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2014	Aug. 25, 2013
Revenue Recorded Upon Shipment [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue	$ 106,240	$ 87,410
Revenue Recorded Upon Acceptance in Foreign Port [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue	26,587	21,389
Revenue from License Fees, R&D Contracts and Royalties/Profit Sharing [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue	212	58
Revenue from Multiple Element Arrangements [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue	575	622
Revenue	$ 133,614	$ 109,479

Note 2 - Investments in Non-public Companies (Details) - USD ($)			1 Months Ended		3 Months Ended
	Jul. 15, 2014	Feb. 15, 2011	Jun. 30, 2010	May 30, 2010	Aug. 31, 2014	Aug. 25, 2013	May 25, 2014	Jul. 16, 2010
Preferred Stock [Member] \| Apio, Inc [Member] \| Windset [Member]
Note 2 - Investments in Non-public Companies (Details) [Line Items]
Investment in Non-Public Company Shares (in Shares)	15,857
Preferred Stock [Member] \| Windset [Member]
Note 2 - Investments in Non-public Companies (Details) [Line Items]
Investment in Non-Public Company Shares (in Shares)	15,857	150,000
Payments to Acquire Investments		$ 15,000,000
Common Stock [Member] \| Apio, Inc [Member] \| Windset [Member]
Note 2 - Investments in Non-public Companies (Details) [Line Items]
Investment in Non-Public Company Shares (in Shares)	68	201
Payments to Acquire Investments		$ 201
Common Stock [Member] \| Windset [Member]
Note 2 - Investments in Non-public Companies (Details) [Line Items]
Investment in Non-Public Company Shares (in Shares)	68	201
Payments to Acquire Investments		$ 201
Senior Preferred Shares [Member] \| Apio, Inc [Member] \| Windset [Member]
Note 2 - Investments in Non-public Companies (Details) [Line Items]
Preferred Stock, Liquidation Preference, Value					$ 15,000,000
Junior Preferred Shares [Member] \| Apio, Inc [Member] \| Windset [Member]
Note 2 - Investments in Non-public Companies (Details) [Line Items]
Preferred Stock, Liquidation Preference, Value					5,100,000
Apio, Inc [Member] \| Windset [Member]
Note 2 - Investments in Non-public Companies (Details) [Line Items]
Payments to Acquire Investments	$ 11,000,000
Preferred Stock, Liquidation Preference, Value					20,100,000
Development Fee			$ 100,000
Annual License Fee Percentage			3.00%
Annual Minimum License Fees			$ 150,000
Aesthetic Sciences [Member]
Note 2 - Investments in Non-public Companies (Details) [Line Items]
Long-term Investments					$ 793,000		$ 793,000	$ 1,800,000
Other than Temporary Impairment Losses, Investments				$ 1,000,000
Windset [Member]
Note 2 - Investments in Non-public Companies (Details) [Line Items]
Investment Ownership Percentage	26.90%				26.90%
Preferred Stock, Dividend Rate, Percentage		7.50%
Investment Income, Dividend					$ 281,000	$ 281,000
Change in Market Value of Investment					200,000	5,400,000
Payments to Acquire Investments					11,000,000
Investment Income, Dividend					$ 281,000	$ 281,000

Note 3 - Stock-Based Compensation (Details) $ in Millions	3 Months Ended
Note 3 - Stock-Based Compensation (Details) $ in Millions	Aug. 31, 2014 USD ($)
Employee Stock Option [Member]
Note 3 - Stock-Based Compensation (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 292 days
Restricted Stock Units (RSUs) [Member]
Note 3 - Stock-Based Compensation (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 219 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)	$ 2.2

Note 3 - Stock-Based Compensation (Details) - Summary of Stock-Based Compensation by Income Statement Line Item - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2014	Aug. 25, 2013
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 12	$ 14
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	386	264
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	133	108
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	265	170
Stock-based compensation expense	$ 398	$ 278

Note 4 - Diluted Net Income Per Share (Details) - shares	3 Months Ended
	Aug. 31, 2014	Aug. 25, 2013
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	336,071	256,264

Note 4 - Diluted Net Income Per Share (Details) - Diluted Net Income Per Share - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Aug. 31, 2014	Aug. 25, 2013
Numerator:
Net income applicable to Common Stockholders (in Dollars)	$ 2,353	$ 4,752
Denominator:
Weighted average shares for basic net income per share	26,840	26,452
Effect of dilutive securities:
Stock options and restricted stock units	427	629
Weighted average shares for diluted net income per share	27,267	27,081
Diluted net income per share (in Dollars per share)	$ 0.09	$ 0.18

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Note 5 - Income Taxes (Details) - USD ($)	3 Months Ended
Note 5 - Income Taxes (Details) - USD ($)	Aug. 31, 2014	Aug. 25, 2013	May 25, 2014
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit)	$ 1,301,000	$ 2,475,000
Effective Income Tax Rate Reconciliation, Percent	36.00%	34.00%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%
Unrecognized Tax Benefits	$ 1,000,000		$ 1,100,000
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$ 850,000		$ 817,000

Note 6 - Inventories (Details) - Inventories - USD ($)
$ in Thousands

Aug. 31, 2014

May 25, 2014

Inventories [Abstract]

Finished goods

$ 14,139

$ 11,111

Raw materials

10,620

10,376

Work in progress

3,075

3,248

Total

$ 27,834

$ 24,735

^[1]

[1]	Derived from audited financial statements.

Note 7 - Debt (Details)	1 Months Ended			3 Months Ended
Note 7 - Debt (Details)	Jul. 17, 2014 USD ($)	May 23, 2012 USD ($)	Apr. 23, 2012 USD ($)	Aug. 31, 2014 USD ($)	Aug. 25, 2013 USD ($)	May 25, 2014 USD ($)
Capital Equipment Loan [Member] \| Apio, Inc [Member]
Note 7 - Debt (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 25,000,000
Long-term Line of Credit				$ 7,100,000
Line of Credit Facility, Amortization Period	7 years
Debt Instrument, Interest Rate, Stated Percentage	3.68%
Each Borrowing Under Equipment Loan [Member] \| Apio, Inc [Member]
Note 7 - Debt (Details) [Line Items]
Debt Instrument, Term	5 years
Amendment [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Apio, Inc [Member]
Note 7 - Debt (Details) [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.75%
Amendment [Member] \| Apio, Inc [Member]
Note 7 - Debt (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 40,000,000
Working Capital Line of Credit [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Note 7 - Debt (Details) [Line Items]
Debt Instrument, Basis Spread on Variable Rate		1.85%
Working Capital Line of Credit [Member]
Note 7 - Debt (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 10,000,000
Line of Credit Facility, Remaining Borrowing Capacity				7,700,000
Long-term Line of Credit				0		$ 0
Line of Credit Facility, Expiration Period		1 year
Line of Credit Facility, Commitment Fee Amount				$ 0	$ 0
Term Loan [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Note 7 - Debt (Details) [Line Items]
Debt Instrument, Basis Spread on Variable Rate		2.00%
Term Loan [Member]
Note 7 - Debt (Details) [Line Items]
Debt Instrument, Term		4 years
Long-term Debt		$ 12,000,000
Debt Instrument, Periodic Payment, Principal		$ 250,000
Remarketing Fee [Member]
Note 7 - Debt (Details) [Line Items]
Annual Re-Marketing Fee Percentage				0.125%
Annual Fees [Member]
Note 7 - Debt (Details) [Line Items]
Annual Letter of Credit Fee Percentage				0.75%
London Interbank Offered Rate (LIBOR) [Member] \| Apio, Inc [Member]
Note 7 - Debt (Details) [Line Items]
Debt Instrument, Basis Spread on Variable Rate			2.00%
Amortization of Loan Origination Fees [Member] \| Apio, Inc [Member]
Note 7 - Debt (Details) [Line Items]
Interest Expense, Other				$ 46,000	47,000
Amortization of Loan Origination Fees [Member] \| Lifecore [Member]
Note 7 - Debt (Details) [Line Items]
Interest Expense, Other				13,000	$ 13,000
Apio, Inc [Member]
Note 7 - Debt (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			$ 25,000,000
Line of Credit Facility, Remaining Borrowing Capacity				$ 27,500,000
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage				0.375%
Long-term Line of Credit				$ 0		0
Capitalized Loan Origination Fees				$ 226,000
Loan Origination Fees, Amortization Period				5 years
Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums				$ 1,100,000		1,000,000
Lifecore [Member]
Note 7 - Debt (Details) [Line Items]
Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums				$ 86,000		98,000
Minimum Fixed Charge Coverage Ratio				1.10
Minimum Quick Ratio				1.25%
Number of Financing Agreements		2
Long-term Debt				$ 40,031,000		$ 34,372,000
Letters of Credit Outstanding, Amount		$ 3,500,000
Minimum Tangible Net Worth				$ 29,000,000

Note 7 - Debt (Details) - Long-term Debt - USD ($)
$ in Thousands

Aug. 31, 2014

May 25, 2014

Real Estate Loan [Member]

Debt Instrument [Line Items]

Debt balance

$ 15,900

$ 16,137

Capital Equipment Loan 1 [Member]

Debt Instrument [Line Items]

Debt balance

9,006

9,430

Capital Equipment Loan 2 [Member]

Debt Instrument [Line Items]

Debt balance

7,070

Term Loan [Member]

Debt Instrument [Line Items]

Debt balance

5,250

6,000

Industrial Revenue Bonds [Member]

Debt Instrument [Line Items]

Debt balance

2,805

Debt balance

40,031

34,372

Less current portion

(6,980)

(6,055)

^[1]

Long-term portion

$ 33,051

$ 28,317

^[1]

[1]	Derived from audited financial statements.

Note 7 - Debt (Details) - Long-term Debt (Parentheticals) - USD ($)	3 Months Ended	12 Months Ended
	Aug. 31, 2014	May 25, 2014
Real Estate Loan [Member]
Debt Instrument [Line Items]
Monthly principal and interest payments (in Dollars)	$ 133,060	$ 133,060
Fixed interest rate	4.02%	4.02%
Capital Equipment Loan 1 [Member]
Debt Instrument [Line Items]
Monthly principal and interest payments (in Dollars)	$ 175,356	$ 175,356
Fixed interest rate	4.39%	4.39%
Capital Equipment Loan 2 [Member]
Debt Instrument [Line Items]
Monthly principal and interest payments (in Dollars)	$ 95,120	$ 95,120
Fixed interest rate	3.68%	3.68%
Term Loan [Member]
Debt Instrument [Line Items]
Monthly payments (in Dollars)	$ 250,000	$ 250,000
Variable interest rate	2.00%	2.00%
Industrial Revenue Bonds [Member]
Debt Instrument [Line Items]
Variable interest rate	0.25%	0.28%

Note 8 - Derivative Financial Instruments (Details) - USD ($)	1 Months Ended
	May 30, 2010	Aug. 31, 2014	May 25, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Asset, Notional Amount	$ 20,000,000
Interest Rate Swap Term	5 years
Derivative, Swaption Interest Rate	4.24%
Derivative, Notional Amount	$ 20,000,000
Derivative Liability, Fair Value, Gross Liability		$ 20,000	$ 44,000

Note 9 - Related Party (Details) - Windset [Member] - USD ($)	3 Months Ended
	Aug. 31, 2014	Aug. 25, 2013	May 25, 2014
Cost of Sales [Member]
Note 9 - Related Party (Details) [Line Items]
Related Party Transaction, Purchases from Related Party	$ 411,000	$ 364,000
Revenue from Related Parties	34,000	$ 32,000
Related Party Transaction, Due from (to) Related Party	338,000		$ 304,000
Accounts Payable, Related Parties	$ 167,000		$ 134,000

Note 10 - Stockholders' Equity (Details) - USD ($) $ in Millions	3 Months Ended
	Aug. 31, 2014	Jul. 14, 2010
Restricted Stock [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	29,496
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	469
Common Stock, Capital Shares Reserved for Future Issuance	3,100,000
Stock Repurchase Program, Authorized Amount (in Dollars)		$ 10
Stock Repurchased During Period, Shares	0

Note 10 - Stockholders' Equity (Details) - Consolidated Statements of Changes in Stockholders’ Equity - USD ($)
$ in Thousands

3 Months Ended

Aug. 31, 2014

Aug. 25, 2013

Common Stock Shares

Balance at May 25, 2014 (in Shares)

^[1]

26,815,253

Stock options exercised, net of shares tendered (in Shares)

469

Vested restricted stock units, net of shares tendered (in Shares)

29,496

Balance at August 31, 2014 (in Shares)

26,845,218

Common Stock

Balance at May 25, 2014

^[1]

$ 27

Balance at August 31, 2014

Additional Paid-in Capital

Balance at May 25, 2014

^[1]

131,488

Stock options exercised, net of shares tendered

Taxes paid by Company for stock swaps and RSUs

(12)

Stock-based compensation expense

398

Tax from stock based compensation expense

(44)

Balance at August 31, 2014

131,833

Retained Earnings

Balance at May 25, 2014

^[1]

71,554

Net income

2,353

$ 4,752

Balance at August 31, 2014

73,907

Non controlling Interest

Balance at May 25, 2014

^[1]

1,692

Non controlling interest in net income

$ 59

Balance at August 31, 2014

$ 1,763

[1]	Derived from audited financial statements.

Note 11 - Business Segment Reporting (Details)	3 Months Ended
Note 11 - Business Segment Reporting (Details)	Aug. 31, 2014	Aug. 25, 2013
Customer 1 [Member] \| Food Products Technology [Member] \| Sales Revenue, Net [Member] \| Customer Concentration Risk [Member]
Note 11 - Business Segment Reporting (Details) [Line Items]
Concentration Risk, Percentage	20.00%	20.00%
Customer 2 [Member] \| Food Products Technology [Member] \| Sales Revenue, Net [Member] \| Customer Concentration Risk [Member]
Note 11 - Business Segment Reporting (Details) [Line Items]
Concentration Risk, Percentage	11.00%	12.00%
Food Products Technology [Member] \| Sales Revenue, Net [Member] \| Customer Concentration Risk [Member]
Note 11 - Business Segment Reporting (Details) [Line Items]
Entity-Wide Revenue Major Customer Number	2	2
Sales Revenue, Net [Member] \| Customer Concentration Risk [Member]
Note 11 - Business Segment Reporting (Details) [Line Items]
Entity-Wide Revenue Major Customer Number	5	5
Concentration Risk, Percentage	46.00%	44.00%
Number of Operating Segments	3

Note 11 - Business Segment Reporting (Details) - Sales by Geograhic Area - USD ($) $ in Millions	3 Months Ended
	Aug. 31, 2014	Aug. 25, 2013
CANADA
Note 11 - Business Segment Reporting (Details) - Sales by Geograhic Area [Line Items]
Segment sales	$ 17.7	$ 9.4
TAIWAN, PROVINCE OF CHINA
Note 11 - Business Segment Reporting (Details) - Sales by Geograhic Area [Line Items]
Segment sales	16.2	12.0
CHINA
Note 11 - Business Segment Reporting (Details) - Sales by Geograhic Area [Line Items]
Segment sales	4.4	1.6
JAPAN
Note 11 - Business Segment Reporting (Details) - Sales by Geograhic Area [Line Items]
Segment sales	2.8	3.2
INDONESIA
Note 11 - Business Segment Reporting (Details) - Sales by Geograhic Area [Line Items]
Segment sales	1.6	2.5
BELGIUM
Note 11 - Business Segment Reporting (Details) - Sales by Geograhic Area [Line Items]
Segment sales		1.2
All Other Countries [Member]
Note 11 - Business Segment Reporting (Details) - Sales by Geograhic Area [Line Items]
Segment sales	$ 3.7	$ 5.3

Note 11 - Business Segment Reporting (Details) - Operations by Business Segment - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2014	Aug. 25, 2013
Food Products Technology [Member]
Segment Reporting Information [Line Items]
Net sales	$ 100,106	$ 79,436
International sales	18,151	9,478
Gross profit	11,854	8,881
Net income (loss)	3,646	7,266
Depreciation and amortization	1,010	1,222
Dividend Income	281	281
Interest income	11	4
Interest expense	338	376
Income tax expense	870	505
Food Export [Member]
Segment Reporting Information [Line Items]
Net sales	26,597	21,398
International sales	26,587	21,389
Gross profit	1,186	1,205
Net income (loss)	271	276
Depreciation and amortization	1	1
Income tax expense	44	78
HA-based Biomaterials [Member]
Segment Reporting Information [Line Items]
Net sales	6,811	8,587
International sales	1,634	4,377
Gross profit	1,048	2,388
Net income (loss)	(1,542)	(376)
Depreciation and amortization	471	584
Interest income	71	56
Interest expense	45	55
Income tax expense	(251)	(106)
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Net sales	100	58
Gross profit	100	58
Net income (loss)	(22)	(2,414)
Depreciation and amortization	31	35
Interest income	11
Income tax expense	638	1,998
Net sales	133,614	109,479
International sales	46,372	35,244
Gross profit	14,188	12,532
Net income (loss)	2,353	4,752
Depreciation and amortization	1,513	1,842
Dividend Income	281	281
Interest income	93	60
Interest expense	383	431
Income tax expense	$ 1,301	$ 2,475